Home | Lungs and Breathing

Lungs and Breathing

Sea traffic pollutes our lungs more than previously thought

New data presented by researchers at Lund University and others in the journal Oceanologia show that the air along the coasts is ...

UC Research Offers New Insights Into a Rare Lung Disease

CINCINNATI—New research from an investigative team at the University of Cincinnati (UC) has identified biomarkers and potential therapeutic approaches that may hold ...

Age of Donor Affects Stem Cell Effectiveness in Repairing Lung Damage from Pulmonary Fibrosis

Miller School of Medicine researchers have found that the age of a donor mouse affects the ability of its mesenchymal stem cells (MSCs) to repair damage to the lungs caused by pulmonary fibrosis. ... Full story

'Dickensian' lung disease rates on the rise in UK pensioners

Chest xrayThe number of people diagnosed with bronchiectasis, a lung condition thought to be a ‘disease of the past’, has risen considerably in the past decade and now affects more than 1% of UK pensioners, according to a new study in the European Respiratory Journal. ... Full story

Smokers with Normal Lung Function Test May Still Be at Risk for Developing Chronic Obstructive Lung Disease

A non-invasive and quick lung function test frequently used to evaluate whether or not a smoker is at risk for developing pulmonary disease is likely mislabeling a significant percentage of smokers as healthy, a research team led by Weill Cornell Medicine investigators suggests. ... Full story

Vaccine Against Respiratory Syncytial Virus (RSV) Shows Promise in Early Trial

Researchers describe a new approach to developing RSV vaccines, reporting promising early results in young children ... Full story

Rocket scientists bring expertise to analyzing breath of sick children

Three rocket-combustion experts teamed up with a pediatrician to engineer a breath analyzer for diseases — a goal that many have tried and failed to reach. ... Full story

Immunovaccine’s vaccine candidate for Respiratory Syncytial Virus is well tolerated in patients in Phase 1 clinical trial

​ Immunovaccine Inc. (“Immunovaccine” or the “Company”) (TSX: IMV; OTCQX: IMMVF), a clinical stage vaccine and immunotherapy company, today announced that safety data from a Phase 1 clinical study showed that its DepoVax™ prophylactic Respiratory Syncytial Virus vaccine candidate (“DPX-RSV”) was well tolerated in the Phase 1 study’s first 20 patients, of which 8 subjects received the DPX-RSV vaccine. This data marks an important milestone for Immunovaccine as it provides the first safety profile of the DepoVax™-based vaccines for infectious diseases in healthy adults. ... Full story

Treating Pulmonary Diseases Using Alaska Pollock Gelatin

Development of Strong Sealant That Remains Liquid at Room Temperature and Helps Shorten Surgical Operations ... Full story

Penn Team Pinpoints Developmental Gene that Regulates Repair and Regeneration in Adult Lungs

New role for hedgehog gene offers better understanding of lung disease ... Full story

1 2 3 4 5 6 7 8 9 10 next last total: 707 | displaying: 1 - 10